Inflapharmacmmoology: Drugs that are effective in treating inflammatory diseases have been developed!

Introduction: In recent years, the targeted treatment of rheumatoid arthritis has developed rapidly, and the prognosis has been greatly improvedHowever, no drug is effective for all patients and has obvious adverse reactions, so the ability to selectively control the body's immune response is a long-term goal for scientists around the worldThe University of Liverpool and AKLRD have developed a new drug, APPA, to make this a reality, according to a study published recently in The Pharmacology of Inflammationrecently, a new study by the University of Liverpool and AKL Research and Development Limited (AKLRD) was published in The Journal of Inflammatory Pharmacology, highlighting the potential benefits of a new drug, APPA, in the human body's inflammatory immune response, which selectively controls the body's immune response by targeting neutrophilsIn many inflammatory cases, such as osteoarthritis, rheumatoid arthritis and, more recently, COVID-19, major complications and extensive tissue damage occur when the immune system is over-activated and uncontrollableFinding new ways to selectively control this overactivity may have significant clinical benefitsneutrophilswe need an effective immune response for health, or we will succumb to overwhelming infections, even routine bacterial infectionsHowever, sometimes even without infection, our immune system becomes overactive and causes damage through inflammationSometimes this can be extremeIn fact, many rheumatoid diseases, such as rheumatoid arthritis and osteoarthritis, are caused by inflammation, and people have long been looking for ways to selectively block the harmful effects of overactive immune systems without blocking our ability to fight infectionneutrophils are the most abundant immune cells in our blood, and they are quickly sent to the infected site, where they do life-saving antibacterial functionby by destroying infected organisms and producing signaling proteins called cytokinesCytokines help coordinate the collection and activity of other immune system cells to fight infectionThere is a lot of evidence in the University of Liverpool's study that these cells are a major contributor to rheumatic diseasescytokine storms and COVID-19in some cases, if cytokine levels are too high, they trigger an extreme inflammatory response, also known as cytokine storms This cytokine storm causes a lot of inflammation and can cause blood vessels to clog or rupture This affects the entire circulatory system, where cytokine storms can cause significant damage, multi-organ failure, sepsis and even death, and appear to play a major role in severe COVID-19 diseases decades of scientists and clinicians have learned about the potential benefits of suppressing neutrophils, but any attempt to do so has failed without weakening the immune system's response to infections APPA APPA is a new drug developed by AKL to treat osteoarthritis, a worldwide disability problem caused by low levels of inflammation The first part of a formal clinical assessment, led by Professor Robert Moots, a rheumatologist in Liverpool, has recently been successfully completed Now, in collaboration with the University of Liverpool and AKL, the drug's effects on neutrophils have been tested and published this study clearly confirms the potential of APPA anti-inflammatory, but does not weaken the host's defenses against infection "We have shown that APPA has the potential to suppress severe inflammation that causes rheumatism, but it does not affect the key antibacterial effects of neutrophils," said Robert Mutz, professor of rheumatology at the University of Liverpool at and director of research and development at Aintree University Hospital.
We waited years for this selective drug Our findings suggest that APPA plays an important role not only in daily treatment for arthritis, but also in COVID-19, in helping to safely regulate aggressive immune responses "Without affecting neutrophils' resistance to infection, treating neutrophils with harmful effects on inflammation has been a long-term goal for many scientists around the world, and ultimately, we may be able to achieve that goal," said Steve Edwards, a neutrophil scientist at the University of Liverpool at the university of
David Miles, ceo of AKL, said these exciting results support positive clinical outcomes observed in patients with osteoarthritis, and also show that APPA plays an important role in treating a wide range of diseases involving inflammation "